Keywords Parole chiave: Cell Migration And Invasion, Epithelial-Mesenchymal Transition, Stemness, Triple-Negative Breast Cancer, Alphavbeta3 Integrin, Psirgdechi
Affiliations Affiliazioni: *** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. billy.hill@ibb.cnr.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. achiara.sarnella@gmail.com., Dipartimento di Farmacia, Universita degli Studi di Napoli "Federico II", 80131 Naples, Italy. domenica.capasso@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. daniela.comegna@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. annarita.delgatto@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. matteo.gramanzini@ibb.cnr.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. sandra.albanese@ibb.cnr.it., Istituto di Cristallografia-CNR, 70126 Bari, Italy. msaviano@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. lzaccaro@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. antonella.zannetti@cnr.it.,
References Riferimenti: Not available. Non disponibili.
Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type
The mesenchymal sub-type of triple negative breast cancer (MES-TNBC) has a highly aggressive behavior and worse prognosis, due to its invasive and stem-like features, that correlate with metastatic dissemination and resistance to therapies. Furthermore, MES-TNBC is characterized by the expression of molecular markers related to the epithelial-to-mesenchymal transition (EMT) program and cancer stem cells (CSCs). The altered expression of alphavbeta(3) integrin has been well established as a driver of cancer progression, stemness, and metastasis. Here, we showed that the high levels of alphavbeta(3) are associated with MES-TNBC and therefore exploited the possibility to target this integrin to reduce the aggressiveness of this carcinoma. To this aim, MES-TNBC cells were treated with a novel peptide, named psiRGDechi, that we recently developed and characterized for its ability to selectively bind and inhibit alphavbeta(3) integrin. Notably, psiRGDechi was able to hamper adhesion, migration, and invasion of MES-TNBC cells, as well as the capability of these cells to form vascular-like structures and mammospheres. In addition, this peptide reversed EMT program inhibits mesenchymal markers. These findings show that targeting alphavbeta(3) integrin by psiRGDechi, it is possible to inhibit some of the malignant properties of MES-TNBC phenotype.
Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type
No results. Nessun risultato.
Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type
14 Records (13 escludendo Abstract e Conferenze). Impact factor totale: 79.281 (73.948 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 65.86 (60.527 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Antonella Zannetti on in data Sunday 12 July 2020, 13:14:40 248 views visite. Last view on Ultima visita in data Friday 26 February 2021, 5:20:58